Thaddeus J. Unger - Concepedia

Author

Thaddeus J. Unger

Karyopharm Therapeutics (United States)ORCID

Also Known As

T Unger, T. J. Unger, T. Unger, T.J. Unger, Thaddeus J Unger, Thaddeus J. Unger, Thaddeus John Unger, Thaddeus Unger

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Karyopharm Therapeutics (United States)Princess Margaret Cancer Centre Rigshospitalet Moffitt Cancer Center The Ohio State University

About

Thaddeus J. Unger is an author at Karyopharm Therapeutics (United States) specializing in medicine, pharmacology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	749
2	Cell Biology	3	3	186
3	Health Sciences	2	2	392
4	Endocrinology	2	2	392
5	Social Sciences	1	1	125

Thaddeus J. Unger

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Selective Deletion of<i>Bdnf</i>in the Ventromedial and Dorsomedial Hypothalamus of Adult Mice Results in Hyperphagic Behavior and Obesity Thaddeus J. Unger, Germán Calderón, Leila Bradley, Journal of Neuroscience NeuroendocrinologyDorsomedial HypothalamusHypothalamic CircuitsObesityMetabolic Syndrome	2007	367
First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors Albiruni R. Abdul Razak, Morten Mau‐Sørensen, Nashat Gabrail, Journal of Clinical Oncology	2016	244
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma Mrinal M. Gounder, Alona Zer, William D. Tap, Journal of Clinical Oncology	2016	161
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma John Kuruvilla, Michael R. Savona, Rachid Baz, Blood	2017	156
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia Ramiro Garzon, Michael R. Savona, Rachid Baz, Blood	2017	147
Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma Nizar J. Bahlis, Heather J. Sutherland, Darrell White, Blood	2018	135
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia Christine Chen, David S. Siegel, Martin Gutierrez, Blood	2017	134
Examination of behavioral deficits triggered by targeting BDNF in fetal or postnatal brains of mice Jason Chan, Thaddeus J. Unger, John Byrnes, Neuroscience Developmental Cognitive NeuroscienceBehavioral NeurosciencePostnatal BrainsNeuropharmacologyBrain Science	2006	125
Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death Trinayan Kashyap, Christian Argueta, Amro Aboukameel, Oncotarget Proteasome InhibitorsChemoprevention StrategyImmunologyCell DeathCancer Biology	2016	125
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials Maria Gavriatopoulou, Ajai Chari, Christine Chen, Leukemia	2020	82

Page 1